JPWO2021154476A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021154476A5 JPWO2021154476A5 JP2022546621A JP2022546621A JPWO2021154476A5 JP WO2021154476 A5 JPWO2021154476 A5 JP WO2021154476A5 JP 2022546621 A JP2022546621 A JP 2022546621A JP 2022546621 A JP2022546621 A JP 2022546621A JP WO2021154476 A5 JPWO2021154476 A5 JP WO2021154476A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- antibody
- represented
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968252P | 2020-01-31 | 2020-01-31 | |
| US62/968,252 | 2020-01-31 | ||
| US202063055405P | 2020-07-23 | 2020-07-23 | |
| US63/055,405 | 2020-07-23 | ||
| PCT/US2021/012666 WO2021154476A1 (en) | 2020-01-31 | 2021-01-08 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023511774A JP2023511774A (ja) | 2023-03-22 |
| JPWO2021154476A5 true JPWO2021154476A5 (https=) | 2024-01-18 |
| JP2023511774A5 JP2023511774A5 (https=) | 2024-01-18 |
| JP7807379B2 JP7807379B2 (ja) | 2026-01-27 |
Family
ID=77079923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546621A Active JP7807379B2 (ja) | 2020-01-31 | 2021-01-08 | 抗トランスフェリン受容体（ｔｆｒ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230113823A1 (https=) |
| EP (1) | EP4096695A4 (https=) |
| JP (1) | JP7807379B2 (https=) |
| KR (1) | KR20220134584A (https=) |
| CN (1) | CN115427059A (https=) |
| AU (1) | AU2021213042A1 (https=) |
| BR (1) | BR112022014771A2 (https=) |
| CA (1) | CA3163290A1 (https=) |
| IL (1) | IL295022A (https=) |
| MX (1) | MX2022009418A (https=) |
| WO (1) | WO2021154476A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| CA3263494A1 (en) * | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| CN119855828A (zh) * | 2023-02-17 | 2025-04-18 | 南京融捷康生物科技有限公司 | 抗TfR1的单域抗体及其用途 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025265092A1 (en) * | 2024-06-21 | 2025-12-26 | Dyne Therapeutics, Inc. | Complexes and uses thereof for treating pompe disease |
| CN120209138B (zh) * | 2025-05-29 | 2025-10-03 | 杭州广科安德生物科技有限公司 | Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| PE20160209A1 (es) * | 2013-08-28 | 2016-05-09 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso |
| EP3221362B1 (en) * | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| PT3325509T (pt) * | 2015-07-22 | 2021-03-12 | Inatherys | Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios |
| AU2016335750B2 (en) * | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
| CA3023930C (en) * | 2016-05-13 | 2025-09-23 | The General Hospital Corporation | TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
| TWI761413B (zh) * | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| IL268836B2 (en) * | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| JP7506601B2 (ja) * | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| AU2019215782A1 (en) * | 2018-02-05 | 2020-07-16 | Jcr Pharmaceuticals Co., Ltd. | Method for delivering drug to muscle |
| AR126019A1 (es) * | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
-
2021
- 2021-01-08 CN CN202180025161.4A patent/CN115427059A/zh active Pending
- 2021-01-08 BR BR112022014771A patent/BR112022014771A2/pt unknown
- 2021-01-08 US US17/796,418 patent/US20230113823A1/en active Pending
- 2021-01-08 KR KR1020227029398A patent/KR20220134584A/ko active Pending
- 2021-01-08 AU AU2021213042A patent/AU2021213042A1/en active Pending
- 2021-01-08 CA CA3163290A patent/CA3163290A1/en active Pending
- 2021-01-08 WO PCT/US2021/012666 patent/WO2021154476A1/en not_active Ceased
- 2021-01-08 JP JP2022546621A patent/JP7807379B2/ja active Active
- 2021-01-08 MX MX2022009418A patent/MX2022009418A/es unknown
- 2021-01-08 IL IL295022A patent/IL295022A/en unknown
- 2021-01-08 EP EP21748405.4A patent/EP4096695A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021154476A5 (https=) | ||
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| EP2421899B1 (en) | Anti-human ror1 antibodies | |
| US9758586B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
| JP7649826B2 (ja) | 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用 | |
| JP2021523874A (ja) | 抗メソセリン抗体およびその抗体薬物コンジュゲート | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| KR20230125042A (ko) | 항-tslp 나노항체 및 이의 응용 | |
| JP7755062B2 (ja) | 新規抗ｌ１ｃａｍ抗体 | |
| CN112166121A (zh) | 神经生长因子的单克隆抗体及其编码基因和应用 | |
| WO2022171134A1 (zh) | 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途 | |
| CN116217728A (zh) | 靶向caix抗原的纳米抗体及其应用 | |
| TW202506189A (zh) | 配體－細胞毒性藥物綴合物及其醫藥用途 | |
| JP2022542088A (ja) | 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途 | |
| US20240075158A1 (en) | Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof | |
| TW202535883A (zh) | 配體–細胞毒性藥物偶聯物及其藥物用途 | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| CN119060184B (zh) | 抗rage抗体及其应用 | |
| CN119285778A (zh) | 抗rage抗体及其应用 | |
| WO2024255815A1 (zh) | 一种抗gpc3抗体或抗原结合片段及其用途 | |
| CN120187752A (zh) | 人源化的l1cam抗体药物偶联物 | |
| AU2015252014A1 (en) | Anti-human ror1 antibodies | |
| TW202432185A (zh) | 配體－細胞毒性藥物綴合物及其藥物用途 | |
| CN119948061A (zh) | 人源化抗Nectin-4抗体 | |
| CN119371542B (zh) | 抗rage抗体及其应用 |